Main Management ETF Advisors LLC Sells 448 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Main Management ETF Advisors LLC reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 8.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,984 shares of the biotechnology company’s stock after selling 448 shares during the quarter. Main Management ETF Advisors LLC’s holdings in Sarepta Therapeutics were worth $606,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Manchester Capital Management LLC increased its holdings in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter valued at about $36,000. Steward Partners Investment Advisory LLC increased its position in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after buying an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after buying an additional 216 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright reduced their target price on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Guggenheim reduced their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. Evercore ISI cut Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price target on the stock. in a report on Thursday, May 8th. Finally, Royal Bank of Canada lowered their price objective on Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a research report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $126.74.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Stock Down 1.3%

Shares of SRPT opened at $35.74 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 52-week low of $34.90 and a 52-week high of $173.25. The company has a market cap of $3.51 billion, a PE ratio of 28.59 and a beta of 0.85. The business has a fifty day moving average of $62.68 and a 200 day moving average of $98.89.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. Sarepta Therapeutics’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.73 earnings per share. On average, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.